(Q35193610)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

review article

1 reference

title

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Peter R. Flatt

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

Finbarr O'Harte

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

author name string

Finbarr P M O'Harte

series ordinal

3

1 reference

7 August 2017

language of work or name

English

0 references

publication date

1 August 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

Biochemical and Biophysical Research Communications

6 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

volume

308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

6 November 2019

page(s)

207-213

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12901855%20AND%20SRC:MED&resulttype=core&format=json

The entero-insular axis in type 2 diabetes--incretins as therapeutic agents

6 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Gastric inhibitory polypeptide and effects of glycation on glucose transport and metabolism in isolated mouse abdominal muscle.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Effect of the entero-pancreatic hormones, gastric inhibitory polypeptide and glucagon-like polypeptide-1(7-36) amide, on fatty acid synthesis in explants of rat adipose tissue

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Reduced incretin effect in type 2 (non-insulin-dependent) diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

The insulinotropic actions of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (7-37) in normal and diabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

The effects of glucose-dependent insulinotropic polypeptide infused at physiological concentrations in normal subjects and Type 2 (non-insulin-dependent) diabetic patients on glucose tolerance and B-cell secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

The effect of glyburide on beta-cell sensitivity to glucose-dependent insulinotropic polypeptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Discovery of amino acid variants in the human glucose-dependent insulinotropic polypeptide (GIP) receptor: the impact on the pancreatic beta cell responses and functional expression studies in Chinese hamster fibroblast cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Degradation, cyclic adenosine monophosphate production, insulin secretion, and glycemic effects of two novel N-terminal Ala2-substituted analogs of glucose-dependent insulinotropic polypeptide with preserved biological activity in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Gastric inhibitory polypeptide: the neglected incretin revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Biological activity of GLP-1-analogues with N-terminal modifications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Interaction of gastric inhibitory polypeptide, glucose, and arginine on insulin and glucagon secretion from the perfused rat pancreas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Glucagon-like peptide-1 7-36: a physiological incretin in man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

DPP IV resistance and insulin releasing activity of a novel di-substituted analogue of glucose-dependent insulinotropic polypeptide, (Ser2-Asp13)GIP.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Analogs of glucose-dependent insulinotropic polypeptide with increased dipeptidyl peptidase IV resistance.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Structure-activity relationships of glucose-dependent insulinotropic polypeptide (GIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Structure-function analysis of a series of novel GIP analogues containing different helical length linkers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Cloning, functional expression, and chromosomal localization of the human pancreatic islet glucose-dependent insulinotropic polypeptide receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Characterization of a novel glucose-responsive insulin-secreting cell line, BRIN-BD11, produced by electrofusion.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Abnormalities of GIP in spontaneous syndromes of obesity and diabetes in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5

Immunoreactive gastric inhibitory polypeptide and K cell hyperplasia in obese hyperglycaemic (ob/ob) mice fed high fat and high carbohydrate cafeteria diets.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-291X%2803%2901361-5